Edition:
United Kingdom

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

266.00SEK
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
266.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
144,788
52-wk High
290.00kr
52-wk Low
180.00kr

Latest Key Developments (Source: Significant Developments)

Hansa Medical Q2 Operating Loss Widens To SEK 58.8 Million
Thursday, 19 Jul 2018 

July 19 (Reuters) - Hansa Medical AB ::Q2 NET REVENUE SEK 0.9 MILLION VERSUS SEK 0.7 MILLION YEAR AGO.Q2 OPERATING LOSS SEK 58.8 MILLION VERSUS LOSS SEK 44.9 MILLION YEAR AGO.  Full Article

Hansa Medical: IdeS Receives Orphan Drug Designation From FDA
Monday, 9 Jul 2018 

July 9 (Reuters) - Hansa Medical AB ::HANSA MEDICAL LEAD CANDIDATE IMLIFIDASE (IDES) GRANTED ORPHAN DRUG DESIGNATION BY THE FDA FOR ANTI-GBM ANTIBODY DISEASE.  Full Article

Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million
Wednesday, 25 Apr 2018 

April 25 (Reuters) - HANSA MEDICAL AB ::Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO.Q1 NET SALES SEK 588,000 VERSUS SEK 1.1 MILLION YEAR AGO.  Full Article

‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Hansa Medical Ab ::‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​.HANSA MEDICAL -COMMISSIONED EVERCORE, RBC CAPITAL AND SEB, TO INVESTIGATE POSSIBILITY OF UNDERTAKING NEW ISSUE OF SHARES TO INSTITUTIONAL INVESTORS.‍INTENDS TO USE PROCEEDS FROM DIRECTED ISSUE TO FUND CONTINUED DEVELOPMENT OF COMPANY'S EXISTING PORTFOLIO​.  Full Article

Hansa Medical Q3 operating loss up at SEK ‍​37.4 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - HANSA MEDICAL AB ::Q3 OPERATING LOSS SEK ‍​37.4 MILLION VERSUS LOSS SEK 27.0 MILLION YEAR AGO.Q3 NET REVENUE SEK ‍​678,000 VERSUS SEK 0.9 MILLION YEAR AGO.  Full Article

Hansa Medical: sudden death of CEO Göran Arvidson​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - HANSA MEDICAL AB :‍ANNOUNCES SUDDEN DEATH OF CEO GÖRAN ARVIDSON​.‍CHAIRMAN ULF WIINBERG WILL SERVE AS ACTING CEO.‍BIRGIT STATTIN NORINDER WILL TAKE OVER ROLE AS CHAIRMAN OF BOARD UNTIL FURTHER NOTICE​.  Full Article

Hansa Medical: preclinical results confirm IdeS potential in cancer immunotherapy
Tuesday, 23 May 2017 

May 23 (Reuters) - HANSA MEDICAL AB :PUBLISHED PRECLINICAL RESULTS CONFIRM IDES POTENTIAL IN CANCER IMMUNOTHERAPY.PUBLISHED PRECLINICAL RESULTS CONFIRM IDES POTENTIAL IN CANCER IMMUNOTHERAPY.PUBLISHED FINDINGS DEMONSTRATE HOW PRE-TREATMENT WITH IDES IN TUMOUR ANIMAL MODELS CAN INCREASE EFFICACY OF CURRENTLY AVAILABLE ANTIBODY BASED CANCER THERAPIES.  Full Article

BRIEF-Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million

* Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO